澳大利亚毒物信息中心报告的COVID-19快速抗原检测试剂暴露临床特征:一项前瞻性研究
该前瞻性研究由新南威尔士毒物信息中心开展,2022年1月22日至2022年8月31日共记录218例COVID-19快速抗原检测试剂暴露,75%(n=164)获得完整随访信息。其中53例为含叠氮化钠产品暴露(35例有随访数据),165例为不含叠氮化钠或成分不明产品暴露(129例有随访数据)。总体以非故意暴露为主(n=182),151例为经口摄入;绝大多数(>90%)未出现症状,出现的症状均为轻度,95%(n=208)无需转诊医疗机构。作者认为症状少可能与试剂盒内叠氮化钠浓度低、体积小有关,但仍需持续毒物监测。
要点
- 218例快速抗原检测试剂暴露中,>90%未出现症状,所有出现的症状均为轻度
- 95%(n=208)的病例无需转诊至医疗机构
- 含叠氮化钠产品暴露53例(35例有随访)与不含叠氮化钠或成分不明产品暴露165例(129例有随访),症状发生均少
- 暴露以非故意为主(n=182),其中151例为经口摄入
- 完整随访信息仅75%(n=164),作者认为仍需持续毒物监测
适用人群与场景
- 2022年1月22日至2022年8月31日期间向新南威尔士毒物信息中心报告的COVID-19快速抗原检测试剂暴露者,共218例,以非故意暴露为主(n=182),151例为经口摄入
研究设计与关键结果
- 前瞻性研究,由新南威尔士毒物信息中心开展,2022年1月22日至2022年8月31日共记录218例COVID-19快速抗原检测试剂暴露,75%(n=164)获得完整随访信息
- 含叠氮化钠产品暴露53例(35例有随访数据),不含叠氮化钠或成分不明产品暴露165例(129例有随访数据)
- 非故意暴露182例,经口摄入151例;绝大多数(>90%)未出现症状,所有出现的症状均为轻度
- 95%(n=208)的病例无需转诊至医疗机构
证据类型、等级与局限
- 证据类型:前瞻性研究
- 局限:完整随访信息仅75%(n=164);作者认为仍需持续毒物监测
对床旁实践的改变
- 作者认为,无论是否含叠氮化钠,快速抗原检测试剂暴露后出现症状者少,可能与试剂盒内叠氮化钠浓度低、体积小有关
- 作者认为仍需持续进行毒物监测
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Coronavirus disease COVID-19 rapid antigen tests are a useful tool in detecting infection, and their use has increased in many countries since they became commercially available in late 2021. Some rapid antigen tests contain sodium azide, which can be toxic in small doses. This study aimed to describe the clinical characteristics of exposures to COVID-19 rapid antigen tests.
METHODS: This is a prospective study conducted by the New South Wales Poisons Information Centre. From 22 January 2022 to 31 August 2022, rapid antigen test exposures were followed up to obtain outcome information. Data collected included: brand/ingredients, exposure route, demographics, symptoms, and disposition.
RESULTS: We recorded 218 exposures in the seven-month study period. Complete follow-up information was available in 75% (n = 164). There were 53 exposures to sodium azide-containing products (35 with follow-up data) and 165 to non-sodium azide-containing products and unknown ingredient exposures (129 with follow-up data). Overall, unintentional exposures predominated (n = 182), and 151 were ingestions. The vast majority (>90%) did not develop symptoms, and all symptoms that developed were mild. Most cases (95%, n = 208) did not require referral to a healthcare facility.
CONCLUSIONS: In this prospective series, few patients developed symptoms, regardless of the sodium azide content, likely due to low concentration and low volume within the test kits. However, ongoing toxicovigilance is warranted.
参考来源
- Chiew K, Wright NE, Cairns R, et al. Clinical features of COVID-19 rapid antigen test exposures reported by an Australian poisons information centre: a prospective study. Clin Toxicol (Phila). 2023. PMID: 37293746. doi:10.1080/15563650.2023.2217337
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。